Weeks after starting, Amgen flashes yellow light on PhIII of $400M eczema bet
Amgen is taking its foot off the pedal just a few weeks after beginning a late-stage trial of a Kyowa Kirin drug for which it dished out $400 million last year in exchange for ex-Japan rights.
The California pharma has paused the Phase III ROCKET-IGNITE study, according to its Japanese partner’s latest earnings report Thursday. The 52-week, 570-patient trial began in June and is expected to collect final primary outcome data in March 2024, according to a federal trials database, which cites the study as active, but not recruiting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.